Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2018 Report; 2018 Available from:https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Accessed 430, 2019.
   Google Scholar
• AdeloyeD, ChuaS, LeeC, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. doi:10.7189/jogh.05.02041526755942
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). The top 10 causes of death. Fact sheet 310; 2017 Updated January 2017 Available from: https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 430, 2019 http://www.who.int/mediacentre/factsheets/fs310/en/.
   Google Scholar
• US Centers for Disease Control and Prevention. National Vital Statistics Reports. Deaths: final data for 2015; 2015 Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_06.pdf. Accessed 244 2018.
   Google Scholar
• European Respiratory Society (ERS). European lung white book - chapter 2: the economic burden of lung disease; 2016 Updated 2016 Available from: http://www.erswhitebook.org/. Accessed 1210 2016 http://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/.
   Google Scholar
• WedzichaJA, SeemungalTA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796. doi:10.1016/S0140-6736(07)61382-817765528
   PubMed Web of Science ®Google Scholar
• DonaldsonGC, SeemungalTA, BhowmikA, WedzichaJA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. doi:10.1136/thorax.57.10.84712324669
   PubMed Web of Science ®Google Scholar
• DonaldsonGC, MullerovaH, LocantoreN, et al. Factors associated with change in exacerbation frequency in COPD. Respir Res. 2013;14:79. doi:10.1186/1465-9921-14-7923899210
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2016; 2016 Available at: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/. Accessed 25, 2016.
   Google Scholar
• CapelM, MarequeM, AlvarezCJ, LindnerL, OyaguezI. Cost-effectiveness of fixed-dose combinations therapies for chronic obstructive pulmonary disease treatment. Clin Drug Investig. 2018;38(7):611–620. doi:10.1007/s40261-018-0646-0
   PubMed Web of Science ®Google Scholar
• WilsonMR, PatelJG, ColemanA, McDadeCL, StanfordRH, EarnshawSR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017;12:997–1008. doi:10.2147/COPD.S12442028392684
   PubMed Web of Science ®Google Scholar
• TebbothA, TernouthA, Gonzalez-RojasN. UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD. Clinicoecon Outcomes Res. 2016;8:667–674. doi:10.2147/CEOR.S11654627853383
   PubMedGoogle Scholar
• van BovenJF, KocksJW, PostmaMJ. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands. Int J Chron Obstruct Pulmon Dis. 2016;11:2191–2201. doi:10.2147/COPD.S11473827703341
   PubMed Web of Science ®Google Scholar
• Selya-HammerC, Gonzalez-Rojas GuixN, BaldwinM, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat(R) fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Ther Adv Respir Dis. 2016;10(5):391–401. doi:10.1177/175346581665727227405723
   PubMed Web of Science ®Google Scholar
• EklundO, AfzalF, BorgstromF, et al. Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK. Clinicoecon Outcomes Res. 2016;8:243–252. doi:10.2147/CEOR.S10557927354818
   PubMed Web of Science ®Google Scholar
• ChanMC, TanEC, YangMC. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1079–1088. doi:10.2147/COPD.S15910329670344
   PubMed Web of Science ®Google Scholar
• TeeA, ChowWL, BurkeC, BasavarajaiahG. Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore. Singapore Med J. 2018;59(7):383–389. doi:10.11622/smedj.201802229546433
   PubMed Web of Science ®Google Scholar
• BjermerL, van BovenJFM, Costa-ScharplatzM, et al. Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population. Respir Res. 2017;18(1):206. doi:10.1186/s12931-017-0688-529228950
   PubMed Web of Science ®Google Scholar
• Reza Maleki-YazdiM, MolimardM, KeiningerDL, et al. Cost effectiveness of the long-acting beta2-adrenergic agonist (LABA)/long-acting muscarinic antagonist dual bronchodilator indacaterol/glycopyrronium versus the LABA/inhaled corticosteroid combination salmeterol/fluticasone in patients with chronic obstructive pulmonary disease: analyses conducted for Canada, France, Italy, and Portugal. Appl Health Econ Health Policy. 2016;14(5):579–594. doi:10.1007/s40258-016-0256-z27516088
   PubMed Web of Science ®Google Scholar
• AsukaiY, BaldwinM, FonsecaT, GrayA, MungapenL, PriceD. Improving clinical reality in chronic obstructive pulmonary disease economic modelling: development and validation of a micro-simulation approach. Pharmacoeconomics. 2013;31(2):151–161. doi:10.1007/s40273-012-0016-323329431
   PubMed Web of Science ®Google Scholar
• HoogendoornM, Corro RamosI, BaldwinM, Gonzalez-Rojas GuixN, Rutten-van MolkenM. Broadening the Perspective of Cost-Effectiveness Modeling in Chronic Obstructive Pulmonary Disease: A New Patient-Level Simulation Model Suitable to Evaluate Stratified Medicine. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2019;22(3):313–321. doi:10.1016/j.jval.2018.10.00830832969
   PubMed Web of Science ®Google Scholar
• GeitonaM, KousoulakouH, KalogeropoulouM, MitsikiE, PanittiE, SteiropoulosP. Cost-effectiveness analysis of the fixed combination indacaterol/glycopyrronium vs. tiotropium and salmeterol/fluticasone in the management of COPD in Greece. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research. 2015;18(7):A500. doi:10.1016/j.jval.2015.09.1414
   Web of Science ®Google Scholar
• PriceD, KeiningerD, Costa-ScharplatzM, et al. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respir Med. 2014;108(12):1786–1793. doi:10.1016/j.rmed.2014.09.01525307414
   PubMed Web of Science ®Google Scholar
• WedzichaJA, BanerjiD, ChapmanKR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa151638527181606
   PubMed Web of Science ®Google Scholar
• HurstJR, VestboJ, AnzuetoA, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa090988320843247
   PubMed Web of Science ®Google Scholar
• BeehKM, GlaabT, StowasserS, et al. Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res. 2013;14(1):116. doi:10.1186/1465-9921-14-11624168767
   PubMed Web of Science ®Google Scholar
• KerkhofM, FreemanD, JonesR, ChisholmA, PriceDB. Predicting frequent COPD exacerbations using primary care data. Int J Chron Obstruct Pulmon Dis. 2015;10:2439–2450. doi:10.2147/COPD.S9425926609229
   PubMed Web of Science ®Google Scholar
• MargüelloMS, GarrastazuR, Ruiz-NuñezM, et al. Independent effect of prior exacerbation frequency and disease severity on the risk of future exacerbations of COPD: a retrospective cohort study. NPJ Primary Care Respiratory Medicine. 2016;26:16046. doi:10.1038/npjpcrm.2016.46
   PubMed Web of Science ®Google Scholar
• MolinariN, BriandC, VachierI, et al. Hospitalizations for COPD exacerbations: trends and determinants of death. Copd. 2015;12(6):621–627. doi:10.3109/15412555.2015.100793126263032
   PubMedGoogle Scholar
• MullerovaH, ShuklaA, HawkinsA, QuintJ. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open. 2014;4(12):e006171. doi:10.1136/bmjopen-2014-006171
   PubMed Web of Science ®Google Scholar
• BlanchetteCM, GrossNJ, AltmanP. Rising costs of COPD and the potential for maintenance therapy to slow the trend. Am Health Drug Benefits. 2014;7(2):98–106.24991394
   PubMedGoogle Scholar
• ChenX, WangN, ChenY, XiaoT, FuC, XuB. Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities. Int J Chron Obstruct Pulmon Dis. 2016;11:2625–2632. doi:10.2147/COPD.S11852327799761
   PubMed Web of Science ®Google Scholar
• PunekarYS, ShuklaA, MüllerovaH. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis. 2014;9:65–73. doi:10.2147/COPD.S5441724426781
   PubMed Web of Science ®Google Scholar
• DhamaneAD, MoretzC, ZhouY, et al. COPD exacerbation frequency and its association with health care resource utilization and costs. Int J Chron Obstruct Pulmon Dis. 2015;10:2609–2618. doi:10.2147/COPD.S9014826664109
   PubMed Web of Science ®Google Scholar
• SouliotisK, KousoulakouH, HillasG, TzanakisN, ToumbisM, VassilakopoulosT. The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece. Int J Chron Obstruct Pulmon Dis. 2017;12:1395–1400. doi:10.2147/COPD.S13282528546747
   PubMed Web of Science ®Google Scholar
• ScanlonPD, ConnettJE, WallerLA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000; 161 (2): 381–390. doi:10.1164/ajrccm.161.2.990104410673175
   PubMed Web of Science ®Google Scholar
• Statistics Sweden. Life expectancy in Sweden 2011–2015. Available from: https://www.scb.se/Statistik/_Publikationer/BE0701_2016A01R_BR_BE51BR1604.pdf. Accessed 425 2018)..
   Google Scholar
• LindbergA, LarssonLG, MuellerovaH, RonmarkE, LundbackB. Up-to-date on mortality in COPD - report from the OLIN COPD study. BMC Pulm Med. 2012;12:1. doi:10.1186/1471-2466-12-122230685
   PubMed Web of Science ®Google Scholar
• Rutten-van MolkenMP, OostenbrinkJB, TashkinDP, BurkhartD, MonzBU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest. 2006;130(4):1117–1128. doi:10.1378/chest.130.4.111717035446
   PubMed Web of Science ®Google Scholar
• LisspersK, LarssonK, JohanssonG, et al. Economic burden of COPD in a Swedish cohort: the ARCTIC study. Int J Chron Obstruct Pulmon Dis. 2018;13:275–285. doi:10.2147/COPD.S14963329391785
   PubMed Web of Science ®Google Scholar
• Swedish Agency for Health Technology Assessment and Assessment of Social Services; 2016 Available from: http://www.sbu.se/en/. Accessed 12 2016.
   Google Scholar
• Garcia-AymerichJ, Serra PonsI, ManninoDM, MaasAK, MillerDP, DavisKJ. Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax. 2011;66(7):585–590. doi:10.1136/thx.2010.15287621515553
   PubMed Web of Science ®Google Scholar
• BermejoI, TappendenP, YounJH. Replicating health economic models: firm foundations or a house of cards? Pharmacoeconomics. 2017;35(11):1113–1121. doi:10.1007/s40273-017-0553-x28748450
   PubMed Web of Science ®Google Scholar
• DrummondM, BarbieriM, CookJ, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value in Health. 2009;12(4):409–418. doi:10.1111/j.1524-4733.2008.00489.x19900249
   PubMed Web of Science ®Google Scholar
• GoereeR, HeJ, O’ReillyD, et al. Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. Clinicoecon Outcomes Res. 2011;3:89–104. doi:10.2147/CEOR.S1440421935337
   PubMedGoogle Scholar
• PriceDB. Time to get real: critical and imperative change required in evidence evaluation. J Thoracic Dis. 2016;8(Suppl 5):S431–434. doi:10.21037/jtd.2016.07.10
   PubMed Web of Science ®Google Scholar
• van der SchansS, GoossensLMA, BolandMRS, et al. Systematic review and quality appraisal of cost-effectiveness analyses of pharmacologic maintenance treatment for chronic obstructive pulmonary disease: methodological considerations and recommendations. Pharmacoeconomics. 2017;35(1):43–63. doi:10.1007/s40273-016-0448-2
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnhartF, BrealeyN, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa171390129668352
   PubMed Web of Science ®Google Scholar
• PapiA, VestboJ, FabbriL, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X29429593
   PubMed Web of Science ®Google Scholar
• The R Foundation. The R project for statistical computing. Available from: https://www.r-project.org/. Accessed 430, 2019 2019.
   Google Scholar
• RStudio I. Shiny. From R Studio; 2019 Available from: https://shiny.rstudio.com/. Accessed 430 2019.
   Google Scholar
• Novartis. Data on file. 2015.
   Google Scholar
• TLV (Dental and Pharmaceutical Benefits Agency S. 2016 Available from: http://www.tlv.se/beslut/sok/lakemedel/. Accessed 622 2016.
   Google Scholar